Streetbeat News

THTX

Theratechnologies Inc.

https://www.theratech.com

Industry

Drug Manufacturers - Specialty & Generic

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Open

1.22

Mkt cap

56M

Volume

420

High

1.22

P/E Ratio

-30.50

52-wk high

2.58

Low

1.22

Div yield

N/A

52-wk low

1.08

Theratechnologies announced a potential temporary supply disruption for EGRIFTA SV in early 2025 due to a voluntary shutdown of a contract manufacturer's facility after an FDA inspection. The company plans to manage inventory to meet demand but expects a $1.6 million revenue shortfall for fiscal year 2024.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 9:03 pm

Theratechnologies announced that their drug sudocetaxel zendusortide showed signs of long-term efficacy and a manageable safety profile in patients with solid tumors, according to an updated analysis from an ongoing Phase 1 clinical trial. The drug induced durable disease stabilization lasting up to 45 weeks beyond treatment completion.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 9:27 pm

Theratechnologies announced it will present long-term efficacy, safety, and pharmacokinetic data on TH1902 (Sudocetaxel Zendusortide), its lead investigational drug for treating solid tumors, at the American Society of Clinical Oncology.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 11:39 am

Theratechnologies (NASDAQ:THTX) reported Q1 EPS of $(0.10), beating the $(0.12) estimate, but missed sales estimates with $16.25M against the expected $20.10M. This represents a 77.27% increase in EPS and an 18.39% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 10, 2024 | 11:33 am

Earnings reports for April 10, 2024, include projections for companies like Delta Air Lines, Altamira Therapeutics, and Rent the Runway, among others. Expectations range from losses to modest profits across various sectors.

Portfolio Pulse from Benzinga Insights

April 10, 2024 | 9:18 am

Theratechnologies announces a phase-down of research activities to focus on its commercial business, leading to a restructuring charge comprising approximately $625,000 in cash charges for severance and other expenses, and about $770,000 in non-cash charges.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 1:39 pm

Theratechnologies Inc. announced it will phase down its preclinical oncology research activities to focus on its Phase 1 clinical trial of sudocetaxel zendusortide in advanced ovarian cancer patients. The company aims to leverage its SORT1+ Technology platform data to attract an R&D partner. It also plans to present preclinical data at the AACR annual meeting. The restructuring is expected to result in charges of approximately $1.395 million during 2024, aligning with its goal of achieving positive Adjusted EBITDA.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 1:39 pm

Theratechnologies forecasts its fiscal year 2024 sales to be between $87M-$90M, which is below the consensus estimate of $92.85M. The company also expects adjusted EBITDA to be between $13M-$15M.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:38 pm

Theratechnologies (NASDAQ:THTX) reported Q4 earnings with losses of $(0.08) per share, surpassing the $(0.24) estimate, and sales of $23.45M, slightly above the $23.36M estimate. This represents an improvement over the previous year's performance.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 12:33 pm

The article lists companies scheduled to report their earnings on February 21, 2024, including their expected earnings per share and revenue. It covers a wide range of industries and includes both companies expected to report profits and losses.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 10:09 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.